How MLN4924 Works: The Anti-Cancer and Anti-Inflammatory Potential of Pevonedistat

MLN4924 (Pevonedistat) is a first-in-class small-molecule inhibitor targeting the NEDD8-activating enzyme (NAE), which plays a critical role in the regulation of protein degradation via the neddylation pathway. Initially developed for cancer therapy, MLN4924 disrupts cell cycle control and induces apoptosis by inhibiting cullin-RING ligases (CRLs). Beyond oncology, emerging studies suggest its potential in modulating immune responses, reducing inflammation, and protecting against organ damage. While promising, its development faces challenges including toxicity, biomarker identification, and variability in therapeutic response. Current research focuses on enhancing efficacy through combination therapies and personalized treatment strategies. MLN4924 remains a versatile and evolving candidate in both cancer and immunological research.

What is MLN4924 (Pevonedistat)?

MLN4924, also known by its investigational name Pevonedistat, is a small-molecule inhibitor that has emerged as a promising therapeutic agent in cancer and inflammatory disease research. It specifically targets the NEDD8-activating enzyme (NAE), a critical component of the neddylation pathway. This pathway is essential for the activation of cullin-RING ligases (CRLs), which regulate the degradation of proteins involved in cell cycle progression, apoptosis, and DNA replication.

By inhibiting NAE, MLN4924 disrupts the neddylation process, leading to the accumulation of CRL substrates such as CDT1, p27, and NRF2. This accumulation causes cellular stress, DNA re-replication, and ultimately cell death, making MLN4924 a potent candidate for treating various cancers, especially those that rely heavily on CRL-mediated protein turnover.

MLN4924 was initially developed by Millennium Pharmaceuticals and later advanced into clinical trials by Takeda Oncology. It has shown therapeutic potential in both hematological malignancies (e.g., acute myeloid leukemia) and solid tumors (e.g., lung, liver, and colorectal cancers). Beyond oncology, recent studies suggest it may also possess anti-inflammatory and neuroprotective effects by modulating immune responses and reducing oxidative stress.

As of 2025, MLN4924 continues to be evaluated in clinical trials, with growing interest in combination therapies involving chemotherapy, radiotherapy, and immunotherapy. Although some Phase III trials faced setbacks due to toxicity and limited efficacy in broad patient populations, MLN4924 remains a focal point in targeted therapy development.

How Does MLN4924 Work? Mechanism of Action Explained

MLN4924 (Pevonedistat) exerts its biological effects by targeting a cellular process called neddylation, a post-translational protein modification critical for cell cycle progression and survival. Specifically, MLN4924 inhibits the NEDD8-activating enzyme (NAE1), which is required to activate NEDD8 — a ubiquitin-like protein that modifies and activates cullin-RING ligases (CRLs).

CRLs are E3 ubiquitin ligases that regulate the degradation of numerous proteins involved in DNA replication, apoptosis, and mitotic control. When MLN4924 blocks NAE1, the neddylation of cullin proteins is prevented, leading to CRL inactivation. As a result, their substrates accumulate within the cell, including:

CDT1: Leads to DNA re-replication and genomic instability

p21/p27: Causes cell cycle arrest

IκBα: Suppresses NF-κB signaling

This disruption causes cellular stress, DNA damage, and ultimately apoptosis, particularly in rapidly dividing tumor cells.

Beyond oncology, MLN4924’s inhibition of neddylation also affects immune regulation and inflammation, suggesting broader therapeutic applications. Importantly, it has shown synergy when used in combination with DNA-damaging agents or radiotherapy, making it an attractive candidate for combination therapies.

However, neddylation is also important in normal cell function. As such, MLN4924’s off-target effects and toxicity profiles are under scrutiny in ongoing clinical trials.

MLN4924 in Cancer Research and Clinical Trials

MLN4924 (Pevonedistat) has garnered considerable attention in oncology for its novel mechanism targeting the neddylation pathway. Preclinical and clinical studies have demonstrated that MLN4924 exerts strong anti-tumor activity by disrupting the function of cullin-RING ligases (CRLs), leading to the accumulation of regulatory proteins that trigger DNA damage, cell cycle arrest, and apoptosis in cancer cells.

Several types of cancer have shown sensitivity to MLN4924, particularly acute myeloid leukemia (AML), where CRLs are often hyperactive. A Phase I clinical trial showed encouraging responses in relapsed/refractory AML patients, prompting further exploration in hematologic malignancies. In solid tumors, MLN4924 has demonstrated efficacy in models of non-small cell lung cancer (NSCLC), colorectal cancer, and oral squamous cell carcinoma.

Importantly, MLN4924 enhances the efficacy of radiotherapy and chemotherapeutic agents by sensitizing tumor cells to DNA-damaging insults. For example, its combination with radiation reversed radioresistance in oral cancers by modulating the neddylation of TGF-β receptors. Similarly, pairing MLN4924 with kinase inhibitors such as PF-3758309 has yielded synergistic anti-proliferative effects.

Despite early success, a Phase III trial in AML did not meet its primary endpoint, raising concerns about toxicity and patient selection. However, emerging research suggests that biomarker-driven approaches may help identify subsets of patients who are more likely to benefit from MLN4924-based regimens.

As of 2025, the oncology community continues to investigate MLN4924 in combination therapies and synthetic lethality screens, which may unlock its full therapeutic potential.

Emerging Uses of MLN4924 Beyond Oncology

While MLN4924 (Pevonedistat) is primarily known for its anti-cancer activity, emerging research has uncovered its therapeutic potential beyond oncology—particularly in inflammation, immune modulation, and neuroprotection.

One promising area is inflammatory disease. MLN4924 has been shown to reduce foam cell formation in atherosclerosis by enhancing autophagy and shifting macrophage metabolism toward an anti-inflammatory phenotype. By inhibiting the neddylation of key transcriptional regulators, it suppresses pro-inflammatory cytokines and cholesterol accumulation in vascular tissues.

In the immune system, MLN4924 modulates T-cell function. It affects CD8+ T-cell metabolism and cytotoxicity, helping to fine-tune immune responses during cancer immunotherapy or organ transplantation. Preclinical studies have shown that MLN4924 treatment can suppress alloimmune responses, potentially improving graft survival and reducing the need for conventional immunosuppressants.

MLN4924 also demonstrates neuroprotective effects, particularly in models of traumatic brain injury (TBI). By modulating neutrophil extracellular traps (NETs) and blood-brain barrier permeability, MLN4924 reduces neuroinflammation and apoptosis. Similarly, it shows benefit in acute kidney injury (AKI) by attenuating p53 and MAPK signaling pathways involved in renal cell death.

There is also evidence that MLN4924 may impact viral latency. For instance, in HIV research, neddylation inhibition has been found to enhance proviral transcription and reactivation, offering a potential avenue for “shock and kill” therapeutic strategies.

These findings broaden MLN4924’s potential as a multi-system modulator, although further clinical studies are needed to evaluate safety and long-term effects in non-oncologic conditions.

Challenges, Safety, and Future Outlook

Although MLN4924 (Pevonedistat) has shown significant promise as a first-in-class NEDD8-activating enzyme inhibitor, its clinical development has encountered several challenges that impact its broader adoption.

A major concern is toxicity. Clinical trials have reported dose-limiting toxicities such as hematologic suppression, hepatic injury, and gastrointestinal complications. In some models, MLN4924 even exacerbated conditions like sepsis, suggesting that the inhibition of neddylation may interfere with essential immune defenses. Furthermore, the failure of a Phase III trial in acute myeloid leukemia (AML) due to lack of significant overall survival benefit has led to cautious reevaluation of its standalone use.

Another hurdle is the lack of predictive biomarkers for patient stratification. Not all tumors respond equally to MLN4924, and identifying molecular features that predict sensitivity—such as alterations in cullin-RING ligases or expression of genes like VOPP1—is essential to improve therapeutic outcomes.

Despite these issues, the future outlook remains positive. Ongoing research focuses on using MLN4924 in combination therapies with radiation, DNA-damaging agents, kinase inhibitors, or immune checkpoint inhibitors. In addition, synthetic lethality screens and multi-omics profiling are helping identify vulnerable cancer subtypes that could benefit most from MLN4924 treatment.

There is also growing interest in repurposing MLN4924 for non-oncologic diseases, including neurodegeneration, autoimmune conditions, and organ transplant rejection, albeit with careful dosing strategies to avoid systemic toxicity.